Asterias Biotherapeutics Inc (NYSE:AST) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 2,635,157 shares, a growth of 7.8% from the July 14th total of 2,444,930 shares. Currently, 9.8% of the shares of the company are sold short. Based on an average trading volume of 181,807 shares, the days-to-cover ratio is currently 14.5 days.

Shares of Asterias Biotherapeutics (AST) traded down 4.35% on Wednesday, reaching $3.30. 33,662 shares of the company traded hands. The stock’s market cap is $162.57 million. Asterias Biotherapeutics has a 52-week low of $2.54 and a 52-week high of $5.80. The stock has a 50 day moving average of $3.48 and a 200 day moving average of $3.50.

AST has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Monday, July 17th. HC Wainwright set a $12.00 target price on shares of Asterias Biotherapeutics and gave the stock a “buy” rating in a report on Monday, June 12th.

TRADEMARK VIOLATION NOTICE: “Asterias Biotherapeutics Inc (AST) Short Interest Update” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.